| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0006-8993(95)01166-8 |
| P698 | PubMed publication ID | 8821747 |
| P50 | author | Daniel E Rusyniak | Q42869909 |
| P2093 | author name string | B A Bennett | |
| C K Hollingsworth | |||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain | Q1073 |
| dopamine | Q170304 | ||
| neurotoxicity | Q3338704 | ||
| toxic encephalopathy | Q7830379 | ||
| P304 | page(s) | 168-176 | |
| P577 | publication date | 1995-12-01 | |
| P1433 | published in | Brain Research | Q4955782 |
| P1476 | title | HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures | |
| P478 | volume | 705 |
| Q36350707 | Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice |
| Q46925688 | Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons |
| Q45722718 | Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization. |
| Q37031214 | Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system. |
| Q35023230 | CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. |
| Q40182651 | D1/NMDA receptors and concurrent methamphetamine+ HIV-1 Tat neurotoxicity |
| Q42457657 | Differences in nocturnal basal and rhythmic prolactin secretion in untreated compared to treated HIV-infected men are associated with CD4+ T-lymphocytes. |
| Q57040576 | Endothelins in inflammatory neurological diseases |
| Q35058518 | Genetic predictor of working memory and prefrontal function in women with HIV. |
| Q27023968 | HIV Associated Neurocognitive Disorders |
| Q34795283 | HIV neurotoxicity: potential therapeutic interventions |
| Q27473387 | HIV-1 associated dementia: symptoms and causes |
| Q48447211 | HIV-1 gp120 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain and HIV-associated dementia |
| Q35743630 | HIV-1 proteins, Tat and gp120, target the developing dopamine system |
| Q39427767 | Human Immunodeficiency Virus Promotes Mitochondrial Toxicity |
| Q45723766 | Human immunodeficiency virus type 1 envelope-mediated neuropathogenesis: targeted gene delivery by a Sindbis virus expression vector |
| Q24673647 | Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase |
| Q45383832 | Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains |
| Q44864998 | Human immunodeficiency virus type 1 protein gp120 causes neuronal cell death in the rat brain by activating caspases. |
| Q38122650 | Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways |
| Q36429675 | Increased Sensitivity to Cocaine Self-Administration in HIV-1 Transgenic Rats is Associated with Changes in Striatal Dopamine Transporter Binding. |
| Q26768068 | Interactions of Opioids and HIV Infection in the Pathogenesis of Chronic Pain |
| Q40313441 | Lentivirus envelope protein exerts differential neuropathogenic effects depending on the site of expression and target cell |
| Q34461686 | Methamphetamine-induced alterations in dopamine transporter function |
| Q36302067 | Molecular and cellular mechanisms of neuronal cell death in HIV dementia |
| Q34306701 | Neuroimmune and neurovirological aspects of human immunodeficiency virus infection |
| Q35177355 | Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS. |
| Q82029838 | Neuropharmacology of HIV/AIDS |
| Q34098776 | Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia |
| Q42493967 | Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum |
| Q37547409 | Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication |
| Q36201412 | Opiate drug use and the pathophysiology of neuroAIDS. |
| Q41866116 | Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. |
| Q43154112 | Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage |
| Q34540563 | Progress in clinical neurosciences: The neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. |
| Q46110293 | Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV. |
| Q34134168 | The gp120 protein is a second determinant of decreased neurovirulence of Indian HIV-1C isolates compared to southern African HIV-1C isolates |
| Q82029739 | The neuropathogenesis of HIV-1 infection |
| Q53828206 | The role of catecholamines in HIV neuropathogenesis. |
| Q30411844 | The role of host genetics in the susceptibility for HIV-associated neurocognitive disorders |
Search more.